Lupin signs licence & supply agreement with Sino Universal Pharma

Global pharma major Lupin signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in the Chinese market, for the treatment of chronic obstructive pulmonary disease (COPD).

As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing of the product.

At 10.56 am, Lupin was trading at Rs. 2,003.95, up by 0.18%, with a volume of 5425 shares on the BSE.